Reinsurance Group of America, Incorporated (RGA) Presents at Barclays 24th Annual Global Financial Services Conference Transcript

RGA CFO Laura Cockrill said the company is continuing to meet its financial targets of 8%-10% EPS growth and 13%-15% ROE. Over the next 12 months, management plans to pursue balanced, disciplined growth by leveraging its local market presence, biometric underwriting expertise and ability to reinsure both sides of insurers' balance sheets. The company also identified improved investor communications as a priority, with no new financial guidance or material operating update disclosed in the excerpt.

Analysis

The investable signal is not the stated target range; it is the new CFO's emphasis on improving the external narrative. For RGA, a sustained valuation rerating requires investors to gain confidence that earnings growth is repeatable across mortality, longevity, capital solutions and asset-intensive reinsurance—not merely a favorable underwriting period. The next 1-3 months should therefore be judged on disclosure quality: segment-level new-business economics, adverse-development cadence, capital deployment priorities and the sensitivity of distributable earnings to credit losses and rate moves.

RGA's differentiated exposure to biometric risk can be advantageous if primary insurers continue to seek capital relief, but it also creates a lagged-loss profile that equity markets tend to discount quickly after any mortality or assumption revision. A stronger investor-relations effort could narrow the conglomerate/complexity discount versus more transparent life insurers, yet communication alone does not change reserve risk. Watch whether quarterly ROE remains within the stated range without reserve releases or unusually favorable investment marks; that is the key falsification test over the next two to four earnings reports.

Near term, this is unlikely to move BCS: Barclays' conference-host role has no discernible earnings read-through. The more relevant relative-value comparison is RGA against life insurers with greater spread-income dependence, including MET, PRU and LNC. If rates decline materially over the next 6-18 months, RGA's underwriting- and fee-oriented diversification may deserve a relative premium, while peers more dependent on reinvestment yields face greater earnings-pressure risk.

Key Decisions for Investors

• Maintain RGA as a watch-to-accumulate rather than chase conference commentary; initiate only after the next earnings release confirms in-range ROE with stable mortality/claims assumptions and no material reserve strengthening.
• Conditional pair trade for a falling-rate environment: long RGA / short LNC or PRU over 6-12 months, sized beta-neutral. Thesis is relative resilience from diversified reinsurance economics; exit if RGA reports adverse biometric development or management reduces its ROE framework.
• Use RGA's next earnings call as a disclosure catalyst: add if management quantifies new-business margins, capital-solutions growth and capital return capacity; avoid adding if guidance relies on broad strategic language without segment-level evidence.
• No action in BCS. The conference participation does not alter Barclays' revenue, capital, or credit outlook.